ArticleJournal of clinical practice and research2026
Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015-2025).
Article in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In recent years, the therapeutic use of Janus kinase (JAK) inhibitors in dermatology, particularly in the management of atopic dermatitis (AD), has expanded markedly. This bibliometric study aimed to characterize research themes, evaluate the scientific productivity of authors and countries, and identify emerging areas that may guide future research in this field over the past decade. Materials and Methods: A bibliometric analysis of JAK inhibitors in AD from 2015 to 2025 was conducted using the Web of Science Core Collection (WoSCC) database as the data source. Bibliometric analyses and data visualizations were performed using CiteSpace, VOSviewer, and the Bibliometrix package in R. Results: A total of 1249 studies were included in the analysis. The cluster plot classified all keywords into 9 categories. Pruritus and alopecia areata (AA) were the most frequently co-occurring keywords alongside atopic dermatitis, while delgocitinib and abrocitinib were the most frequently investigated JAK inhibitors. The United States produced the highest number of publications over the past decade. Oregon Health and Science University emerged as one of the most significant contributors to global collaborations, while the Icahn School of Medicine had the highest number of publications, reaching approximately 175 by 2025. Simpson EL emerged as both the most influential and the most cited author in the field, as reflected by citation impact, followed by Emma Guttman-Yassky. Conclusion: Janus kinase (JAK) inhibitors represent one of the most effective and trending therapeutic classes in AD. These agents are not only highly effective for AD but also show promising efficacy in other dermatologic conditions, such as AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.